SCHEMBL4407360

SCHEMBL4407360

CCONC(=O)c1cc(OC)cc(-c2cc3cnc(Nc4ccc(N5CCOCC5)cc4)nc3n(CC)c2=O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 2/20 0.53
CCND1 P24385 2/20 0.53
CCND2 P30279 2/20 0.53
CCND3 P30281 2/20 0.53
CSF1R P07333 4/20 0.51
DAPK1 P53355 2/20 0.51
WEE1 P30291 1/20 0.49
PAK1 Q13153 3/20 0.49
PKN1 Q16512 2/20 0.49
PAK4 O96013 1/20 0.49
FGFR1 P11362 3/20 0.48
LCK P06239 1/20 0.47
PDGFRB P09619 1/20 0.46
SLC2A1 P11166 1/20 0.46
SRC P12931 1/20 0.46
PDGFRA P16234 1/20 0.46
PKMYT1 Q99640 1/20 0.46
PAK3 O75914 2/20 0.46
PAK2 Q13177 2/20 0.46
JAK2 O60674 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13593184 0.88 SRC (0.57) CSF1RDAPK1FGFR1LCKSRC
SCHEMBL13593186 0.82 SRC (0.58) CSF1RDAPK1FGFR1LCKSRC
SCHEMBL4466126 0.81 CDK4 (0.53) CDK4CCND1CCND2CCND3CSF1R
SCHEMBL13593182 0.81 SRC (0.54) CSF1RDAPK1FGFR1LCKSRC
SCHEMBL13593193 0.78 FGFR1 (0.49) FGFR1FGFR4
SCHEMBL4399224 0.77 FGFR4 (0.41) FGFR1SRCRIPK2ACVR1NOD2
SCHEMBL4331732 0.77 FGFR1 (0.40) FGFR1SRCRIPK2ACVR1NOD2
SCHEMBL13593197 0.76 FGFR4 (0.55) CSF1RDAPK1FGFR1LCKJAK2
SCHEMBL14381295 0.75 SRC (0.45) CSF1RDAPK1FGFR1LCKSRC
SCHEMBL13593190 0.75 SRC (0.48) FGFR1SRCFGFR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312321-A1 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS IRM LLC (BM) 2009-12-17 US disclosed
US-20090312321-A1 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS IRM LLC (BM) 2009-12-17 US disclosed
US-20090312321-A1 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS IRM LLC (BM) 2009-12-17 US disclosed
EP-2018167-A2 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS IRM LLC (BM) 2009-01-28 EP disclosed
WO-2007136465-A2 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS IRM LLC (BM) 2007-11-29 WO disclosed
WO-2007136465-A2 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS IRM LLC (BM) 2007-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312321-A1 COMPOSITIONS AND METHODS FOR FGF RECEPTOR KINASES INHIBITORS PTK2B, SGK2, FRK CDK4 477/4885CCND1 2912/4885CCND2 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.